Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Clinical Trials

Potential treatments for macular degeneration must go through a lengthy series of human clinical trials before seeking approval by the U.S. Food and Drug Administration.

Information about clinical trials for the United States as well as clinical trials occurring globally are available at www.clinicaltrials.gov.

Our Phase I/II clinical trials started in December 2011. Learn More.


Join our mailing list and receive updated information as it becomes available:

Avalanche Raises Additional Funding in Follow-On Financing

November 22, 2013

Avalanche announced the completion of additional financing in a round consisting of both new and existing investors. Specific details of the financing, which included both preferred stock and convertible debt, were not disclosed. “Avalanche’s BioFactoryTM platform is based on powerful technology that will help address patients suffering from blinding diseases,” said Thomas Chalberg, Avalanche’s co-founder and CEO... Read More

Read All Avalanche News